8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 30, 2026·SEC
Bicara Therapeutics Inc. Common Stock(BCAX)Earnings, Financials & Key Ratios
BCAX•NASDAQ
Price updated Jun 19, 2026
AboutBicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.Show more
- Revenue$0
- EBITDA-$155M-88.9%
- Net Income-$138M-102.9%
- EPS (Diluted)-2.52-101.6%
- ROE-30.88%-61.3%
BCAX Key Insights
Bicara Therapeutics Inc. Common Stock (BCAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BCAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCAX Price & Volume
Bicara Therapeutics Inc. Common Stock (BCAX) stock price & volume — 10-year historical chart
Loading chart...
BCAX Growth Metrics
Bicara Therapeutics Inc. Common Stock (BCAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-70.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.48%
Return on Capital
10 Years-31.2%
5 Years-31.2%
3 Years-31.2%
Last Year-32.65%
BCAX Recent Earnings
Bicara Therapeutics Inc. Common Stock (BCAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (29%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.93-45.3%
$0.64
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.68+5.6%
$0.72
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.67-21.8%
$0.55
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.50+7.4%
$0.54
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.93vs $0.64-45.3% | — |
| Q2 2026 | Mar 26, 2026 | $0.68vs $0.72+5.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.67vs $0.55-21.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.54+7.4% | — |
Based on last 12 quarters of dataView full earnings history →
BCAX Peer Comparison
Bicara Therapeutics Inc. Common Stock (BCAX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 | |
 ERAS | 4.25B | 13.67 | -31.07 | -77.01% | 0.14 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare BCAX vs Peers
Bicara Therapeutics Inc. Common Stock (BCAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCAX Income Statement
Bicara Therapeutics Inc. Common Stock (BCAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - |
Operating Expenses | 37.66M | 39.89M | 82.39M | 155.6M | 174.06M |
OpEx % of Revenue | - | - | - | - | - |
Selling, General & Admin | 6.34M | 9.27M | 18.77M | 30.51M | 35.8M |
SG&A % of Revenue | - | - | - | - | - |
Research & Development | 31.31M | 30.62M | 63.62M | 125.1M | 111.11M |
R&D % of Revenue | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -37.66M▲ 0% | -39.89M▼ 5.9% | -82.39M▼ 106.5% | -155.6M▼ 88.9% | -174.06M▲ 0% |
Operating Margin % | - | - | - | - | - |
Operating Income Growth % | - | -5.93% | -106.55% | -88.87% | - |
EBITDA | -37.65M | -39.87M | -82.33M | -155.5M | -173.97M |
EBITDA Margin % | - | - | - | - | - |
EBITDA Growth % | - | -5.91% | -106.5% | -88.87% | -59.99% |
D&A (Non-Cash Add-back) | 10K | 19K | 56K | 105K | 86K |
EBIT | -37.73M | -39.89M | -82.39M | -155.6M | -169.67M |
Net Interest Income | -108K | 1.31M | 14.58M | 17.87M | 16.94M |
Interest Income | 4K | 1.31M | 14.58M | 17.87M | 16.94M |
Interest Expense | 112K | 0 | 0 | 0 | 0 |
Other Income/Expense | -188K | -12.09M | 14.58M | 17.87M | 16.94M |
Pretax Income | -37.84M▲ 0% | -51.98M▼ 37.4% | -67.81M▼ 30.5% | -137.73M▼ 103.1% | -157.12M▲ 0% |
Pretax Margin % | - | - | - | - | - |
Income Tax | 1K | 5K | 187K | 217K | 93K |
Effective Tax Rate % | -0% | -0.01% | -0.28% | -0.16% | -0.06% |
Net Income | -37.84M▲ 0% | -51.98M▼ 37.4% | -68M▼ 30.8% | -137.95M▼ 102.9% | -157.31M▲ 0% |
Net Margin % | - | - | - | - | - |
Net Income Growth % | - | -37.36% | -30.8% | -102.88% | -70.38% |
Net Income (Continuing) | -37.84M | -51.98M | -68M | -137.95M | -157.21M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.73▲ 0% | -1.00▼ 37.0% | -1.25▼ 25.0% | -2.52▼ 101.6% | -2.59▲ 0% |
EPS Growth % | - | -36.99% | -25% | -101.6% | -68.48% |
EPS (Basic) | -0.73 | -1.00 | -1.25 | -2.52 | - |
Diluted Shares Outstanding | 51.76M | 51.76M | 54.42M | 54.68M | 60.72M |
Basic Shares Outstanding | 51.76M | 51.76M | 54.42M | 54.68M | 60.72M |
Dividend Payout Ratio | - | - | - | - | - |
BCAX Balance Sheet
Bicara Therapeutics Inc. Common Stock (BCAX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Total Current Assets | 4.98M | 231.07M | 502.53M | 422.05M | 544.91M |
Cash & Short-Term Investments | 4.16M | 230.44M | 489.71M | 414.8M | 539.75M |
Cash Only | 4.16M | 230.44M | 489.71M | 96.69M | 323.46M |
Short-Term Investments | 0 | 0 | 0 | 318.12M | 216.29M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - |
Other Current Assets | 68K | 100K | 12.82M | 7.25M | 5.16M |
Total Non-Current Assets | 1.72M | 2.91M | 66.66M | 8.94M | 8.68M |
Property, Plant & Equipment | 636K | 815K | 845K | 2.03M | 1.77M |
Fixed Asset Turnover | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 117.42M |
Other Non-Current Assets | 1.08M | 2.09M | 6.62M | 6.91M | 6.91M |
Total Assets | 6.7M▲ 0% | 233.98M▲ 3390.7% | 569.2M▲ 143.3% | 430.99M▼ 24.3% | 553.6M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x |
Asset Growth % | - | 3390.71% | 143.26% | -24.28% | 89.79% |
Total Current Liabilities | 23.9M | 15.09M | 17.99M | 28.95M | 39.34M |
Accounts Payable | 5.14M | 3.19M | 4.51M | 5.51M | 6.19M |
Days Payables Outstanding | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 607K | 1.12M | 1.14M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 9.79M | 22.32M | 32.01M |
Current Ratio | 0.21x | 15.32x | 27.93x | 14.58x | 13.85x |
Quick Ratio | 0.21x | 15.32x | 27.93x | 14.58x | 13.85x |
Cash Conversion Cycle | - | - | - | - | - |
Total Non-Current Liabilities | 85K | 389K | 59.33M | 593K | 301K |
Long-Term Debt | 0 | 0 | 0 | 593K | 301K |
Capital Lease Obligations | 0 | 372K | 131K | 0 | 1.16M |
Deferred Tax Liabilities | 0 | 0 | 59.2M | 0 | 0 |
Other Non-Current Liabilities | 85K | 17K | 0 | 0 | 0 |
Total Liabilities | 23.98M | 15.47M | 77.32M | 29.54M | 39.64M |
Total Debt | 0 | 657K | 738K | 1.71M | 1.44M |
Net Debt | -4.16M | -229.78M | -488.97M | -94.97M | -322.02M |
Debt / Equity | - | 0.00x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | 1.85x |
Interest Coverage | -336.89x | - | - | - | - |
Total Equity | -17.28M▲ 0% | 218.51M▲ 1364.7% | 491.88M▲ 125.1% | 401.45M▼ 18.4% | 513.96M▲ 0% |
Equity Growth % | - | 1364.66% | 125.11% | -18.38% | 321.65% |
Book Value per Share | -0.33 | 4.22 | 9.04 | 7.34 | 8.46 |
Total Shareholders' Equity | -17.28M | 218.51M | 491.88M | 401.45M | 513.96M |
Common Stock | 2K | 2K | 7K | 0 | 8K |
Retained Earnings | -101.04M | -153.02M | -221.02M | 0 | -415.18M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | -243K |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
BCAX Cash Flow Statement
Bicara Therapeutics Inc. Common Stock (BCAX) cash flow — operating, investing & free cash flow history
| Metric | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|
Cash from Operations | -32.08M | -45.63M | -74.75M | -106.83M | -116.24M |
Operating CF Margin % | - | - | - | - | - |
Operating CF Growth % | - | -42.25% | -63.83% | -42.92% | -181.08% |
Net Income | -37.84M | -51.98M | -68M | -137.95M | -157.31M |
Depreciation & Amortization | 10K | 19K | 56K | 406K | 355K |
Stock-Based Compensation | 810K | 1.9M | 7.4M | 15.01M | 11.55M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | 14.06M | -77K | 895K | 7.3M |
Working Capital Changes | 4.95M | -9.62M | -14.13M | 14.81M | 21.87M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 2.64M | 0 | 19.7M |
Cash from Investing | -192K | -586K | -9K | -318.45M | -217.51M |
Capital Expenditures | -192K | -586K | -71K | -280K | -340K |
CapEx % of Revenue | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - |
Other Investing | 0 | 0 | 62K | 0 | 0 |
Cash from Financing | 31.7M | 272.5M | 334.03M | 32.26M | 195.15M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 31.54M | 272.35M | 332.43M | 32.26M | 195.15M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 |
Other Financing | 160K | 149K | 1.6M | 0 | 0 |
Net Change in Cash | -573K▲ 0% | 226.28M▲ 39590.8% | 259.27M▲ 14.6% | -393.03M▼ 251.6% | -138.6M▲ 0% |
Free Cash Flow | -32.27M▲ 0% | -46.21M▼ 43.2% | -74.82M▼ 61.9% | -107.11M▼ 43.2% | -116.58M▲ 0% |
FCF Margin % | - | - | - | - | - |
FCF Growth % | - | -43.22% | -61.9% | -43.16% | -31.97% |
FCF per Share | -0.62 | -0.89 | -1.37 | -1.96 | -1.92 |
FCF Conversion (FCF/Net Income) | 0.85x | 0.88x | 1.10x | 0.77x | 0.74x |
Interest Paid | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 1K | 0 | 0 | 0 | 0 |
BCAX Key Ratios
Bicara Therapeutics Inc. Common Stock (BCAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|
Return on Equity (ROE) | -51.67% | -19.14% | -30.88% | -35.89% |
Return on Invested Capital (ROIC) | - | -2129.28% | -75.44% | -71.3% |
Debt / Equity | 0.00x | 0.00x | 0.00x | 0.00x |
FCF Conversion | 0.88x | 1.10x | 0.77x | 0.74x |
Related:BCAX Dividend History·BCAX Revenue History·BCAX Price History·BCAX P/E History·BCAX Financial Ratios·BCAX Institutional Holders
BCAX SEC Filings & Documents
Bicara Therapeutics Inc. Common Stock (BCAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCAX Frequently Asked Questions
Bicara Therapeutics Inc. Common Stock (BCAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bicara Therapeutics Inc. Common Stock (BCAX) grew revenue by 0.0% over the past year. Growth has been modest.
Bicara Therapeutics Inc. Common Stock (BCAX) reported a net loss of $157.3M for fiscal year 2025.
Dividend & Returns
Bicara Therapeutics Inc. Common Stock (BCAX) has a return on equity (ROE) of -30.9%. Negative ROE indicates the company is unprofitable.
Bicara Therapeutics Inc. Common Stock (BCAX) had negative free cash flow of $116.6M in fiscal year 2025, likely due to heavy capital investments.